Genmab stock surges 9% following positive phase 3 ovarian cancer trial results
Summary
Shares of Genmab experienced a nine percent increase following successful late-stage clinical trial results for an ovarian cancer treatment. The positive data from the phase three study drove the significant upward movement in the company's stock value on the market.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.